Analysis of Circulating Exosomes in Melanoma Patients

Centre Hospitalier Universitaire de Besancon150 enrolled

Overview

The hypothesis is that PD-L1\[Programmed Death-Ligand 1\] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Melanoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Melanoma patients admitted in Besançon University Hospital * exigible for immunotherapy such as anti PD-L1/PD-1 * Age ≥18 years * Affiliation to a social security system, Exclusion Criteria: * Minor patients * Patients who have expressed their opposition to the reuse of their data and biological samples

Locations (1)

CHU de Besançon

Besançon, France

Outcomes

Primary Outcomes

Quantification of circulating exosomes

Dosage of proteic biomarkers in circulating exosomes, plasma and tumor tissues. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation

Time frame: Day 1

Secondary Outcomes

PDL1 marking

Compare PD-L1 labeling in exosomes to PD-L1 labeling in plasma and in tumor tissue. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation

Time frame: Day 1

Other proteins detection

Identify other proteins of interest in circulating exosomes. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation.

Time frame: Day 1

Determine whether the initial exosome concentration (at T0) is associated with a response to treatment.

Dosage of PD-L1 in circulating exosomes. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.